Anavex Life Sciences (NASDAQ:AVXL) Upgraded at Wall Street Zen

Anavex Life Sciences (NASDAQ:AVXL) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other analysts have also recently issued reports about the stock. Jones Trading cut shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research note on Friday, October 24th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Anavex Life Sciences in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anavex Life Sciences in a report on Monday, December 29th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Anavex Life Sciences in a research report on Monday, February 9th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $22.00.

Anavex Life Sciences Stock Performance

Anavex Life Sciences stock opened at $3.93 on Friday. The business’s fifty day moving average is $4.26 and its two-hundred day moving average is $6.87. The firm has a market cap of $364.19 million, a P/E ratio of -8.54 and a beta of 1.21. Anavex Life Sciences has a 52 week low of $2.86 and a 52 week high of $13.99.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. On average, equities research analysts predict that Anavex Life Sciences will post -0.69 earnings per share for the current year.

Hedge Funds Weigh In On Anavex Life Sciences

Several hedge funds have recently added to or reduced their stakes in the stock. Stifel Financial Corp boosted its holdings in Anavex Life Sciences by 95.1% during the fourth quarter. Stifel Financial Corp now owns 101,020 shares of the biotechnology company’s stock worth $360,000 after buying an additional 49,229 shares during the last quarter. Rafferty Asset Management LLC raised its position in shares of Anavex Life Sciences by 44.2% in the 4th quarter. Rafferty Asset Management LLC now owns 156,301 shares of the biotechnology company’s stock valued at $556,000 after acquiring an additional 47,873 shares during the period. Integrated Wealth Concepts LLC bought a new position in Anavex Life Sciences during the 4th quarter worth approximately $46,000. State Street Corp grew its holdings in Anavex Life Sciences by 33.4% during the fourth quarter. State Street Corp now owns 4,383,406 shares of the biotechnology company’s stock valued at $15,605,000 after purchasing an additional 1,096,288 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Anavex Life Sciences by 17.5% during the fourth quarter. Wells Fargo & Company MN now owns 133,820 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 19,950 shares during the period. Institutional investors and hedge funds own 31.55% of the company’s stock.

Trending Headlines about Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and raised near‑term and FY2026 EPS forecasts, signaling improved analyst confidence and a $20 target that could support upside. HC Wainwright Reiterates “Buy” Rating for Anavex Life Sciences (NASDAQ:AVXL)
• Positive Sentiment: HC Wainwright raised Q2–Q4 and FY2026 EPS estimates (e.g., Q4 from -$0.14 to -$0.11; FY from -$0.46 to -$0.33), suggesting expected operational or clinical progress that could improve future profitability. What is HC Wainwright’s Estimate for AVXL Q1 Earnings?
• Positive Sentiment: Zacks upgraded AVXL to a Rank #2 (Buy), reflecting growing optimism about the company’s earnings outlook and potentially attracting buy‑side interest. Anavex Life Sciences (AVXL) Upgraded to Buy
• Positive Sentiment: Anavex’s latest quarterly report beat EPS expectations (reported -$0.06 vs. consensus -$0.10), a near‑term fundamental positive that can support price momentum. MarketBeat AVXL profile
• Neutral Sentiment: Reports show a spike in short‑interest figures that are recorded as 0 shares and NaN changes — data appears erroneous or incomplete, so it’s unclear whether short covering or new shorts are influencing trading. (No reliable source link available.)
• Negative Sentiment: Despite upgrades, consensus still forecasts negative FY2026 EPS (-$0.69 before HC Wainwright adjustments), and the stock sits below both the 50‑day (~$4.27) and 200‑day (~$6.92) moving averages, indicating technical resistance and lingering macro/sector risk. MarketBeat AVXL profile

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.